The government is investing £133 million in healthcare innovation including gene-based therapies and artificial intelligence.
The government has today unveiled details of its £133 million investment in life-changing treatments for arthritis and cancer and for pioneering gene-based therapies for diseases including dementia and Parkinson’s.
£50 million will be for NHS diagnostic services and support the work of existing Centres of Excellence in digital pathology and imaging with artificial intelligence. The centres – based in Leeds, Oxford, Coventry and London – will be able to partner with more NHS Trusts and further develop cutting edge products using digital systems and artificial intelligence that could ultimately save lives.
Adult social care will also receive a new cash injection of £7.5 million to use research to improve care delivery for some of the most vulnerable people in our society and £14 million for bioscience projects and technologies across the UK that could, for example, treat osteoarthritis and develop new vaccines.
Business Secretary Andrea Leadsom said “Chronic and painful illnesses like arthritis and Parkinson’s are dreadful and prevent people from living a full life.”
“Curing these kinds of debilitating illnesses is one of the great challenges we face globally, and today’s commitment will play a vital role in ensuring that our scientists and thinkers have the tools they need to find new treatments that will support people to lead longer, healthier lives.”
Health Secretary Matt Hancock said “We’ve got to bring NHS technology into the 21st century. I’ve seen for myself how better technology and diagnosis can save clinicians’ time so they can concentrate on care. The NHS is now spearheading world-leading technologies that can transform and save lives through new treatments, diagnosis techniques and care. I’m determined that the benefits of these advances will improve the lives of thousands of patients whose conditions have long been considered life-limiting.”
A further £69.5 million of the total investment through UK Research and Innovation (UKRI) will help fund 4 British projects:
- Nucleic Acid Therapy Accelerator: ‘NATA’ (£30 million) – brand new therapies and technologies directly targeting genetic mutations could be rolled out to treat diseases including cancer, Huntingdon’s, Parkinson’s and arthritis
- The Advanced Pain Discovery Platform (£12 million) – deepening our understanding of pain, this will reveal new treatment approaches and address a wide spectrum of chronic and debilitating conditions including arthritis. Versus Arthritis will contribute an additional £12 million over 3 years
- UK Centre of Evidence Implementation in Adult Social Care (£7.5 million) – using high quality research, this project will lead to improvements in the delivery of social care across the UK; implementing innovations with the potential to allow more people to receive care from the comfort of their own home
- Tackling Multimorbidity at scale (£20 million, of which the National Institute of Health Research (NIHR) is contributing £10 million) – this research into multimorbidity – when someone is suffering 2 or more long-term health conditions – will propel forward drug development, allow for earlier diagnosis and reduce progression to more severe illness and disability
